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Arterial reconstruction with cryopreserved
human allografts in the setting of infection:
A single-center experience with midterm follow-up
Katherine E. Brown, DO, Kamaldeep Heyer, MD, Heron Rodriguez, MD, Mark K. Eskandari, MD,
William H. Pearce, MD, and Mark D. Morasch, MD, Chicago, Ill
Objectives: Vascular reconstruction in the setting of primary arterial or prosthetic graft infection is associated with
significant morbidity and mortality. Cryopreserved human allografts (CHA) may serve as acceptable alternatives when
autogenous or extra-anatomic/in situ prosthetic reconstructions are not possible.
Methods: Between February 1999 and June 2008, 57 CHAs were placed in 52 patients (average age, 65 years) for
abdominal aortic (n  18) or iliofemoral/femoral-popliteal arterial or prosthetic infections (n  39). Indications for
arterial reconstruction included infected implanted prosthetic material (n  39), mycotic pseudoaneurysms (n  14), or
intra-abdominal bacterial contamination or wound infection (n  4). Wide local debridement and culture was followed
by allograft interposition, bypass, or extra-anatomic reconstruction. Over a similar time period, 53 non-CHA extra-
anatomical prosthetic or in situ autogenous tissue reconstructions were performed in 53 patients (average age, 65 years)
for abdominal aortic (n  18) or iliofemoral and femoral-popliteal (n  35) prosthetic graft infections. Indications for
arterial replacement in all cases included infected implanted prosthetic material.
Results: Thirty-day mortality for all CHA and non-CHA reconstructions was 5.2% and 7.5%, respectively. The 1-year
procedure-relatedmortality for all CHA and non-CHA procedures was 7.0% and 13.2%, respectively. In the CHA cohort,
5 patients required re-exploration for hemorrhage or anastomotic disruption. In midterm CHA follow-up (20 months),
there was 1 graft thrombosis, 2 graft stenoses, 1 recurrent ilioenteric fistula, and 1 non-related amputation. The
remainder of the CHA reconstructions remained patent without evidence of aneurysmal change or reinfection.
Conclusion: In the setting of infection, cryopreserved human allograft arterial reconstruction is a viable alternative to
traditional methods of vascular reconstruction in patients without available autogenous conduit and when expedient
reconstruction is required. In midterm follow-up, cryopreserved allografts appear to be resistant to subsequent
reinfection, thrombosis, or aneurysmal dilatation. However, larger patient populations and longer follow-up are needed
to determine if arterial reconstruction with CHA is the safest and most durable method of treatment for arterial
infections. ( J Vasc Surg 2009;49:660-6.)Revascularization following arterial or prosthetic graft
excision in the setting of infection remains one of the most
challenging problems encountered by surgeons. While pri-
mary arterial infections are uncommon, infection associated
with bioprosthetic material can occur in up to 3% of im-
planted materials.1,2 Accepted methods of vascular recon-
struction in the setting of sepsis have been associated with
high rates of major complications including graft failure,
graft reinfection, amputation, hemorrhage, and death.
Promising results with the use of cryopreserved human
allografts (CHA) for in situ arterial reconstruction have
been reported by some centers. On the other hand, there
have also been reports of human allograft arterial degener-
ation, hemorrhage, and thrombosis, which have prevented
widespread use. The primary aim of this retrospective re-
view was to compare a single-center’s early and late out-
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660comes in patients undergoing arterial reconstruction with
CHA vs an accepted alternative method in the setting of
primary or secondary arterial infection. We hypothesize
that arterial reconstruction with CHA will result in im-
proved early outcomes in this complex patient population.
In addition, the long-term integrity of the allografts will
prevent repeat interventions for reinfection, aneurysmal
degeneration, or graft thrombosis.
PATIENTS AND METHODS
From February 1999 to June 2008, patients treated at
Northwestern Memorial Hospital for intra-abdominal or
lower extremity peripheral primary or secondary arterial
infections were reviewed. A retrospective review of a pro-
spective database was conducted according to Institutional
Review Board protocols specific to the institution. Avail-
able data included patient demographics, original and re-
constructive operative details, perioperative imaging, and
bacteriology results. Follow-up data was obtained from
patient charts, outpatient visits, imaging results, and from
the Social Security Death Index. Primary arterial infection
was defined as infection suspected from blood or wound
culture results, imaging findings, and clinical presentation
in the absence of implanted prosthetic material in the
affected arterial bed. Secondary arterial infection was diag-
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other foreign material within the affected arterial bed. All
patients underwent computed tomography scans or mag-
netic resonance angiography (MRA) preoperatively, except
in the setting of acute rupture with hemodynamic instabil-
ity. Intestinal endoscopy and angiography were performed
in select patients with suspected enteric or ureteral fistulae.
Patients treated by implantation of human cadaveric arterial
allografts were selected for analysis and compared to pa-
tients treated with extra-anatomic prosthetic or autogenous
tissue reconstructive procedures. Patients were further cat-
egorized according to the anatomic location and type of
conduit used for arterial reconstruction. Four separate pa-
tient groups were created for comparison (Table I).
Operative details. The choice of conduit for both
aortic and non-aortic reconstruction was made by the op-
erating surgeon on the basis of the patient condition and
individual preference. Intra-operative tissue and graft cul-
tures were obtained on all patients. Wide debridement and
irrigation were performed on the infected arterial bed.
Cryopreserved human allograft conduits were obtained
from CryoLife, Inc (Kennesaw, Ga) or Regeneration Tech-
nologies, Inc (Alachua, Fla). A supply of frozen aortic and
femoral CHA segments are maintained on-site for use at all
times. Attempts were made to match donor and recipient
blood types when possible and allografts were chosen to
Table I. Anatomic location and conduit used for arterial
reconstruction
Conduit used for arterial
reconstruction
Location of reconstruction
(proximal to distal arterial
anastomosis) n
Cryopreserved human
allograft
Aortic (n  18) Aorta to iliac 11
Aortic tube graft 2
Aortic patch 3
Aorta to femoral 2
Peripheral (n  39) Iliac to femoral 17
Femoral to femoral 8
Femoral artery patch
angioplasty
6
Femoral to AK popliteal 4
Femoral to BK popliteal 2
Common carotid replacement 1
Extra-anatomic
prosthetic material
or autogenous
tissue
Aortic (n  18) Axillary to femoral 18
Peripheral (n  35) Femoral artery patch
angioplasty
11
Femoral to tibial 9
Femoral to AK popliteal 5
Femoral to BK popliteal 2
Iliac to femoral 2
Axillary to popliteal 5
Axillary to femoral 1
AK, Above the knee; BK, below the knee.best match the recipient patient’s anatomic measurements.Anastomoses were performed with polypropylene sutures
and, in select cases, pledgets fashioned from CHA rem-
nants. Appropriate thawing and rinsing techniques were
performed according to distributor instructions. Fresh ca-
daveric allografts were not used. Operative drains were
placed when the surgeon deemed it necessary for continual
drainage. All patients were administered perioperative
broad-spectrum antibiotics until specific bacteriology was
available. The duration of antibiotic administration prior to
excision of the arterial infection was variable as many pa-
tients were treated at outside facilities prior to definite
operative care at our institution. When bacteria were iden-
tified, patients received pathogen-specific postoperative an-
tibiotics for a minimum of 6 weeks. Select patients were
administered treatment for an extended period of time
based on recommendations from an infectious disease spe-
cialist.
Aortic reconstruction. A total of 36 patients (average
age, 70 years, range, 51-85 years) were diagnosed with
primary or secondary infection located in the intra-abdominal
aorta or aorto-iliofemoral segments. In situ CHA aortic
reconstruction was completed in 17 patients with the prox-
imal anastomosis located in sub-diaphragmatic aorta and
distal anastomoses located at the aortic, iliac, or femoral
positions; 1 patient presented with an aortoenteric fistulae
(AEF) and died prior to completion of the CHA recon-
struction from hemodynamic collapse/septic shock. The
18 patients in the non-CHA aortic reconstruction group all
underwent axillofemoral reconstruction with oversewing of
the aorta. The demographics of the two groups were similar
without any statistically significant differences (Table II).
In situ CHA aortic reconstruction was successfully per-
formed with aortoiliac (16) or thoracic (1) aortic cryopre-
served human allografts. The etiologies for the various
arterial infections are detailed in Table III. Eleven patients
presented with infected bioprosthetic material in the aor-
toiliac position: infected aortic bifurcated or tube graft (n
5), infected aortic stent graft (n  2), aortoenteric fistulae
(n  2), and infected iliac stents (n  2). Seven patients
presented with primary aortic infections. All patients under-
went excision of the infected arterial segment and all pros-
thetic material. Omental coverage of the implanted allo-
Table II. Characteristics of patients with aortic
reconstruction
Variable
CHA aortic
n  18 (%)
Extra-anatomic
n  18 (%)
Average age ( SD) 69 years  10 70 years  8
Male gender 13 (72) 13 (72)
Age 80 years 3 (17) 2 (11)
Hypertension 18 (100) 15 (83)
Diabetes mellitus 4 (22) 4 (22)
Dialysis dependence 0 (0) 2 (11)
Current tobacco use 9 (50) 7 (40)
Immunocompromised 1 (6) 1 (6)
CHA, Cryopreserved human allografts; SD, standard deviation.graft was performed when feasible. In 2 patients, the CHA
JOURNAL OF VASCULAR SURGERY
March 2009662 Brown et alaortic segment was not long enough for bilateral femoral
anastomoses, so aortouniiliac bypass followed by an addi-
tional femoral-to-femoral bypass also using CHA segments
was performed in order to restore flow to both lower
extremities.
In all cases, axillary to femoral prosthetic bypass proce-
dures were performed first followed by aortic and iliac
resection. All patients presented with infected bioprosthetic
material: infected aortic bifurcated or tube graft (n  10),
infected aortic stent graft (n 3), aortoenteric fistulae (n
5) (Table III). Five patients underwent excision of only the
infected limb of an implanted bifurcated aortic graft while
the remainder of the patients underwent complete excision
of the infected prosthetic material with aortic stump clo-
sure.
Peripheral reconstruction. A total of 74 procedures
were performed (average age, 64 years, range, 23-84 years)
for non-aortic arterial infection. The patient demographics
are detailed in Table IV. The peripheral group included
patients with an arterial infectious process located in the
iliofemoral or femoral popliteal location, and the recon-
Table III. Indications for arterial reconstruction
Conduit and location for
arterial reconstruction
Etiology of primary or
secondary arterial infection n
Aortic reconstruction
CHA conduit (n  18) Mycotic AAA or
pseudoaneurysm
7
Infected prosthetic material 11
Extra-anatomic (n  18) Infected prosthetic material 18
Iliofemoral/peripheral/other
reconstruction
CHA conduit (n  39) Infected prosthetic graft 28
Mycotic pseudoaneurysm 7
Wound bed contamination 4
Extra-anatomic/autogenous
tissue conduit (n 35)
Infected prosthetic graft 35
CHA, Cryopreserved human allografts; AAA, abdominal aortic aneurysm.
Table IV. Characteristics of patients with peripheral
reconstruction
Variable
CHA Iliofemoral/
peripheral/other
reconstruction
n  39 (%)
Extra-anatomic/
autogenous
iliofemoral/
peripheral
reconstruction
n  35 (%)
Average age ( SD) 64 years  17 63 years  13
Male gender 24 (62) 21 (60)
Age 80 years 7 (18) 3 (9)
Hypertension 28 (72) 29 (83)
Diabetes mellitus 11 (28) 18 (51)
Dialysis dependence 2 (5) 5 (14)
Current tobacco use 15 (38) 24 (69)
Immunocompromised 10 (26) 7 (20)
CHA, Cryopreserved human allografts; SD, standard deviation.structive proximal and distal anastomoses were located inthe iliac or femoral artery, and the femoral and popliteal
arterial location, respectively. A CHA group was compared
to patients with arterial infection located similarly in the
iliofemoral or peripheral location where reconstruction was
performed either by an extra-anatomic prosthetic or autog-
enous tissue reconstruction (Table I).
A total of 39 CHA peripheral reconstructive operations
were successfully performed in the iliofemoral, femoral,
carotid, or visceral location for various indications as de-
tailed in Table III. Femoral-popliteal arterial CHA seg-
ments were implanted in this group. The majority of arterial
infections were secondary to infected bioprosthetic mate-
rial: infected prosthetic graft (n  18), enteral/ureteral
fistulae associated with prosthetic graft or stent (n  4),
infected arterial closure device (n  3), and infected stent
(n 3). Wound bed contamination from intestinal or fecal
spillage, traumatic wounds, or intra-abdominal abscesses
(n 4), and mycotic pseudoaneurysms (n  7) comprised
the remainder of the patients. Additional muscle flap cov-
erage was performed in 21 patients. Postoperative antico-
agulation was not used.
A total of 35 non-CHA procedures were performed for
infected bioprosthetic material in the iliofemoral or femoral
popliteal location: infected prosthetic graft (n  32), in-
fected stent (n  2), and infected arterial closure device
(n  1). Arterial reconstruction was performed with an
extra-anatomically tunneled prosthetic graft, autogenous
vein, or endarterectomized superficial femoral artery (Table
I). Prosthetic material was excised completely when possi-
ble. Muscle flap coverage was performed in 12 patients.
Postoperative anticoagulation was used in patients with
prosthetic material terminating below the knee.
Follow-up. Patients were evaluated at 1 month, 6
months, and yearly thereafter with computed tomography
angiography (CTA) or magnetic resonance angiography
(MRA) for aortic-iliac reconstruction and duplex ultra-
sonography for peripheral reconstructions. In addition,
patients were evaluated clinically at similar or more fre-
quent time intervals.
RESULTS
The total overall 30-day death rate was 5.3% and 7.5%
for CHA operations and non-CHA operations, respec-
tively. The overall procedure-related mortality at 1 year for
CHA and non-CHA operations was 7.0% and 13.2%, re-
spectively.
Aortic reconstruction
Early outcomes (Table V). The 30-day mortality for
CHA and non-CHA aortic reconstructions was 11.1% and
22.2%, respectively. The procedure-related mortality for
CHA and non-CHA aortic reconstructions was 11.1% and
27.8%, respectively. In the CHA group, 1 patient with an
AEF died intraoperatively prior to successful allograft im-
plantation. The second death in the CHA cohort was an
85-year-old patient with an infected aortic endoprosthesis
who died after successful implantation of an aortobiiliac
CHA graft. This patient developed a severe coagulopathy,
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died on postoperative day 28. Additional morbidity in-
cluded renal failure requiring hemodialysis (n 4, 22.2%),
cardiac complications (n  2, 11.1%), and respiratory fail-
ure (n  3, 16.7%).
In the non-CHA aortic reconstruction group, 4 pa-
tients died within 30 days from the index operation. All 4
died from multisystem organ failure. Renal failure requiring
hemodialysis, cardiac complications, and respiratory failure
occurred in 4 (22.2%), 4 (22.2%), and 1 (5.6%) patients,
respectively. One patient underwent amputation and 2
patients required reoperation for bleeding from axillary
anastomoses. The average length of stay for CHA and
non-CHA reconstruction patients was 16 and 17 days,
respectively. Bacterial and fungal isolates are detailed in
Table VI.
Late outcomes. The mean follow-up for CHA aortic
reconstruction was 25 months. No patients were lost to
follow-up. Three CHA patients died for reasons not related
to their aortic reconstruction. One died from persistent
sepsis and endocarditis at 3 months. After 5 years, 1 patient
died from lung cancer and 1 died from heart disease. A
stenotic lesion was detected on MRA 9 months after allo-
graft implantation at the anastomotic site of an allograft
superior mesenteric artery (SMA) branch sewn to a native
left renal artery. This was successfully treated with angio-
plasty and stent placement. One patient who had a CHA
aortobiiliac reconstruction for an infected prosthetic graft
developed a fistula between his rectal stump remnant and
his allograft iliac limb. During operative exploration for
rectal bleeding, a fistula was discovered between the rectal
stump and the iliac anastomosis where two allograft seg-
ments had been sewn end-to-end in order to extend the
treatment length. The CHA was excised and an extra-
anatomic axillo-bifemoral reconstruction was performed.
Of the remaining patients, there have been no amputations
or clinical or radiological evidence of CHA aneurysmal
degeneration or reinfection.
The mean follow-up for non-CHA aortic reconstruc-
Table V. Major outcomes at 30-days for aortic
reconstruction
Complication
CHA aortic
n  18 (%)
Extra-anatomic
n  18 (%)
Death 2 (11.1) 4 (22.2)
Respiratory failure 3 (16.7) 1 (5.6)
Cardiac 2 (11.1) 4 (22.2)
Renal failure requiring
hemodialysis 4 (22.2) 4 (22.2)
Graft occlusion/thrombosis 0 (0) 1 (5.6)
Hematoma/hemorrhage
from graft 0 (0) 2 (11.1)
Wound dehiscence/infection 2 (11.1) 3 (15.7)
Graft reinfection 0 (0) 0 (0)
Deep venous thrombosis 1 (5.6) 2 (11.1)
Amputation 0 (0) 1 (5.6)
CHA, Cryopreserved human allografts.tion was 14 months. Only 8 patients from the original 18are still alive. Two patients died from complications of
coronary artery disease and 1 patient died from prolonged
systemic sepsis and multisystem organ failure. The remain-
ing 7 patients’ cause of death could not be determined.
One axillofemoral graft occluded multiple times and the
patient required thoracofemoral bypass. No additional
signs of graft reinfection and no additional need for ampu-
tation have been identified.
Peripheral reconstruction
Early outcomes (Table VII). The 30-day mortality
rate for CHA and non-CHA reconstructions in the peripheral
position were 2.6% and 0%, respectively. The procedure-
related mortality for CHA and non-CHA peripheral recon-
structions was 5.1% and 5.7%, respectively. One CHA
patient died on postoperative day 17 from multisystem
organ failure secondary to persistent bacteremia, respira-
tory failure, and acute myocardial infarction. An additional
patient died from cardiac and pulmonary complications 6
weeks after the CHA operation. Graft-related hemorrhage
occurred in a total of 5 CHA patients. On postoperative day
1, 3 patients were emergently re-explored for groin bleed-
ing. One was found to have suture disruption, 1 patient had
bleeding from a loose suture line and 1 patient had bleeding
from an allograft side branch; all of these cases were suc-
cessfully treated with suture repair. One additional patient
was emergently explored on postoperative day 3 for bleed-
ing and found to have complete anastomotic disruption of
Table VI. Bacterial isolates from excised prosthetic
material or wound base
Location and conduit for
arterial reconstruction Organism n
Aortic reconstruction Mixed organisms 9
None isolated 10
Staphylococcus aureus 5
Propionibacterium acnes 3
Staphylococcus aureus,
oxacillin resistant
3
MRSA 2
VRE 1
Pseudomonas aeruginosa 1
Escherichia coli 1
Staphylococcus epidermidis 1
Iliofemoral/peripheral
reconstruction
None isolated 25
Staphylococcus aureus 11
Mixed organisms 10
Staphylococcus aureus,
oxacillin resistant
6
Pseudomonas aeruginosa 5
MRSA 5
VRE 3
Escherichia coli 3
Candida albicans 2
Serratia marrescens 2
Enterobacter cloacae 1
Streptococcus pneumonia 1
MRSA, methicillin resistant staphylococcus aureus; VRE, vancomycin resis-
tant enterococcus.a CHA to prosthetic graft anastomosis. Total excision of
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performed. The final hemorrhagic complication occurred
in an AIDS patient with a history of external beam groin
radiation. This patient underwent an ipsilateral femoral-to-
femoral CHA bypass and muscle flap coverage for a mycotic
aneurysm. He returned 2 months later with groin hemor-
rhage from a disruption in the side of the allograft not
associated with the anastomosis. The wound bed appeared
grossly infected without any signs of healing. Culture re-
sults were positive for oxacillin-resistant staphylococcus
aureus and streptococcus. Despite attempt at primary repair
and replacement of the muscle flap, the graft blew out 3
days later and required complete excision. This patient died
3 months later in hospice from persistent sepsis. One pa-
tient with a CHA femoral-to-femoral bypass suffered graft
occlusion on postoperative day 35 from poor inflow. One
patient with no option for distal reconstruction underwent
a lower extremity amputation with a patent profunda fem-
oral arterial reconstruction using allograft.
Of the non-CHA peripheral reconstructive group, 6
patients required lower extremity amputation in the early
postoperative period. Three patients underwent reopera-
tion for immediate graft thrombosis. Four patients under-
went reoperation for wound hematoma or anastomotic
disruption. The average length of stay for CHA and non-
CHA reconstruction was 17 and 13 days, respectively.
Bacterial and fungal isolates are detailed in Table VI.
Late outcomes. The mean follow-up for the periph-
eral CHA group and non-CHA group was 18 and 26
months, respectively. A total of 12 patients in the CHA
group and 15 patients in the non-CHA group died during
the follow-up period. Causes of death in patients with
implanted allografts were as follows: cancer (n 4), perfo-
rated viscus (n  1), cirrhosis (n  1), coronary artery
Table VII. Major outcomes at 30-days for peripheral
reconstruction
Complication
CHA Iliofemoral/
peripheral/other
n  39 (%)
Extra-anatomic/
autogenous
iliofemoral/
peripheral
n  35 (%)
Death 1 (2.6) 0 (0)
Respiratory failure 4 (10.3) 3 (8.6)
Cardiac 3 (7.7) 3 (8.6)
Renal failure requiring
hemodialysis 2 (5.1) 0 (0)
Cerebrovascular accident 0 (0) 1 (2.9)
Graft occlusion/thrombosis 0 (0) 3 (8.6)
Hematoma/hemorrhage
from graft 4 (10.3) 4 (11.4)
Wound
dehiscence/infection 6 (15.4) 4 (11.4)
Graft reinfection 0 (0) 1 (2.9)
Deep venous thrombosis 0 (0) 1 (2.9)
Amputation 1 (2.6) 6 (17.1)
CHA, Cryopreserved human allografts.disease (n 1), and unknown (n 3). In the CHA group,one iliofemoral graft thrombosed at 15 months. This pa-
tient had a known thrombophilia and had discontinued
warfarin therapy 1 month prior. One iliofemoral allograft
bypass stenosis occurred at 12 months postoperatively. The
patient presented with ipsilateral calf claudication and re-
fused further intervention. The cause of death for the
majority of the non-CHA group was not known. In the
non-CHA patient group, 3 patients presented with graft
reinfection and an additional 3 patients underwent reop-
eration for graft failure. Three patients ultimately required
amputation.
DISCUSSION
The ideal solution to revascularization in the setting of
arterial infection would be an operation in which elimina-
tion of arterial sepsis and restoration of in-line flow could be
performed in an expedient manner using a readily available
conduit that is resistant to reinfection, thrombosis, and is
free from late aneurysmal degeneration. The aim of this
study was to evaluate a single center experience using
cryopreserved human arterial allografts for arterial recon-
struction in comparison to traditional reconstruction in the
form of extra-anatomical bypass or autogenous tissue in the
setting of arterial infection. Our hypothesis is that biologi-
cal tissue in the form of cryopreserved human allografts may
be a conduit with these desired properties and thus can be
used in this high-risk population of patients with arterial
infection. Additionally, human allografts can be implanted
in an expedient manner with acceptable perioperative mor-
bidity and mortality and long term durability when com-
pared to the traditional ex-situ bypass grafting.
Cryopreserved human allografts have gone through a
number of modifications since transition from the use of
fresh human allografts for aortic reconstruction. Fresh al-
lograft rupture, disintegration, and aneurysmal degenera-
tion resulted in postoperative catastrophic events that
caused their use to be abandoned after early cases of arterial
reconstruction for infection.3 The use of cryopreserved
cadaveric allografts by cardiovascular surgeons for arch and
valve reconstruction in the setting of endocarditis4,5 have
stimulated new interest for use in other anatomical loca-
tions. Cryopreservation techniques have permitted the
preparation, storage, and sterilization of human arterial and
venous segments from brain-dead donors for future use in
live patients without risk of a host immune response or
donor-to-recipient infection. Fresh human allografts are no
longer used for arterial reconstruction, thus eliminating
many of the previous complications such as immune-
mediated degeneration and aneurysmal degeneration with
subsequent rupture.6
The most widely accepted procedure for arterial recon-
struction in the setting of vascular sepsis is extra-anatomic
bypass grafting in a sterile field with either immediate or
staged complete excision of infected prosthetic material or
arterial tissue. This method of reconstruction requires pro-
longed operative time and the long-term patency of these
grafts is less than optimal. In addition, aortic excision
carries the risk of fatal aortic stump blow-out with reported
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patency rates of 73% have been reported, while other
groups have reported patency as low as 43% at 3 years.8-10
In our extra-anatomic aortic group, graft thrombosis oc-
curred at a rate of 5% in the immediate postoperative period
and 1 additional patient underwent graft revision for occlu-
sion after 30 days. This is compared to the CHA aortic
reconstruction patients who suffered no graft thrombosis
or amputation in early and late follow-up. Some reports
have suggested that allografts are prone to thrombosis
because of a host response to the substance of the graft. In
our patient population, allograft failure was not directly
related to the allograft conduit; the two cases of graft
thrombosis were secondary to advanced inflow occlusive
disease and an untreated thrombophilic condition.
Autogenous deep femoral and saphenous veins for the
creation of a neoaortoiliac system (NAIS) have been used
because of the obvious benefits of use of non-prosthetic or
biological tissue for arterial in situ reconstruction. Clagett
et al11-13 described this procedure and reported acceptable
patency rates in the short-term without evidence of graft
reinfection and a recent study by Beck et al14 reviewed
long-term data for over 240 NAIS reconstructions and
reported a 5-year primary patency rate of 82%. In exchange
for the benefits of in situ reconstruction with biological
tissue, this procedure requires more operative time and can
be complicated by venous insufficiency and lower extremity
compartment syndrome.15
Antibiotic-soaked polyester prosthetic graft is an alter-
nate conduit which can be used for in situ aortic reconstruc-
tion. Despite the benefits of expedient restoration of in-line
flow to the lower extremities, reinfection rates exceed
10%16-18 and thus have not been widely implanted for
arterial sepsis.
Anastomotic disruption has been described with the
use of cryopreserved human allografts. In our series, 2
patients with peripheral reconstruction developed allograft
degeneration in the face of persistent sepsis in the wound
bed. Vogt et al19 reported complications of allograft degen-
eration in inadequately drained operative fields specifically
with intra-abdominal infection and suggested additional
postoperative drainage to control sepsis. CHA aortic anas-
tomotic disruption has been reported in the setting of
allograft reconstruction for aortoenteric fistulae AEF.20-24
It has been hypothesized that in addition to virulent organ-
isms, contamination from enteric contents may accelerate
allograft degeneration.
Anastomotic disruption secondary to allograft anasto-
mosis to non-autogenous tissue was a problem that was
identified in this series but has only been described in one
other report.25 It remains to be seen if CHA can be
anastomosed successfully to any tissue other than non-
infected native arterial tissue. Vogt et al19 have proposed
gentamicin-bonded fibrin glue and allograft strip reinforce-
ment of a tension-free anastomosis and allograft to recipi-
ent-appropriate sizing to prevent anastomotic disruption.
Our center’s practice now is to perform only native arterial
to allograft anastomoses because of our experience withfailed prosthetic-allograft anastomoses. Postoperative hem-
orrhage after a CHA reconstruction may also result from
inadequate ligation or suture closure of the allograft side
branches. This has not been widely reported by other
authors with the use of CHA arterial conduits, however, it
is a complication specific to the use of CHA. To that end, it
is imperative that all allograft side branches are inspected
carefully for hemostasis after arterialization of the graft.
There were no cases of aneurysmal degeneration during
allograft follow-up. The durability of allografts has been
excellent since the advent of cryopreservation.6,20,26-28 Ste-
nosis did occur in two instances at locations of small arterial
caliber. Since the diameters of an arterial allograft conduit
are larger than that of saphenous vein, allograft stenoses
appear rare. In our experience, such lesions can be treated
endoluminally with angioplasty and stents.
Overall, the compared patient groups (CHA vs non-
CHA) were demographically similar and equal in terms of
early major postoperative complications, length of hospital
stay, late mortality. If comparisons are made between the
total number of graft-related complications (graft throm-
bosis, hemorrhage, reinfection, and amputation) including
both the immediate 30-day postoperative period and the
1-year postoperative period, there is a difference between
the two reconstructive cohorts as a whole in favor of
allograft reconstruction. The total graft-related morbidity
for peripheral reconstructions was 17.9% and 57.1% for the
CHA and non-CHA groups, respectively. The total graft-
related morbidity for aortic reconstructions was 11.8% and
27.8% for the CHA and non-CHA groups, respectively.
This would suggest that there may be a benefit to CHA
reconstruction as it pertains to reoperative procedures and
the fate of the graft in the short term. Even though these
percentages look promising, the retrospective nature of this
review as well as the small patient groups and limited
duration of follow-up are major limitations to this study. In
addition, the heterogeneity of the patient groups prevents
adequate statistical analysis. The method of arterial recon-
struction was not standardized and was based on the pref-
erence of the surgeon and the condition of the patient. This
could have resulted in a bias for one type of reconstruction
over another such as potentially favoring an extra-anatomic
reconstruction in the setting of a virulent organism or more
advanced arterial infections. Despite this, early data reveals
an acceptable perioperative risk of major complications and
death in the CHA groups when compared to other ac-
cepted methods of revascularization. In order to defini-
tively conclude that CHA reconstruction is superior to an
extra-anatomic reconstruction would require a standard-
ized patient population, prospectively randomized to either
treatment group; unfortunately a trial of this nature would
not be possible with this type of patient population.
In conclusion, CHA reconstruction in the aortic or
non-aortic position offers the benefit of in situ reconstruc-
tion with biological tissue and is associated with low risk of
reinfection, thrombosis, and aneurysmal degeneration in
midterm follow-up. Arterial reconstruction with allografts
in the setting of persistent arterial sepsis or direct anasto-
JOURNAL OF VASCULAR SURGERY
March 2009666 Brown et almosis of allograft to non-arterialized tissue may result in a
higher risk of anastomotic disruption and thus should not
be performed. However, the use of CHA seems as an
acceptable method of arterial reconstruction when com-
pared to the standard treatment methods. Long-term
follow-up and larger patient groups are required for
improved outcome data.
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